Perspective Therapeutics, Inc.
CATX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000728387
In the last 90 days, Perspective Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 131 institutions reported holding it in 13F filings for Q2 2026, worth $297.6M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Perspective Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 43 | 35 | −8 |
| Shares | 16.8M | 16.1M | −704.2K (−4.2%) |
| Value | $5.19M | $3.70M | −$1.49M (−28.7%) |
New holders (0)
Institutions that held Perspective Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
None.
Sold out (8)
Institutions that held Perspective Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Venator Capital Management Ltd. | 550,000 | $170.0K |
| Susquehanna International Group, LLP | 35,327 | $11.0K |
| Two Sigma Securities, LLC | 31,729 | $10.0K |
| Virtu Financial LLC | 24,471 | $8.00K |
| Jane Street Group, LLC | 20,774 | $6.00K |
| Bank of America Corp | 1,000 | $0 |
| Chilton Capital Management LLC | 500 | $0 |
| Northwestern Mutual Wealth Management Co | 82 | $0 |